Biocartis Group NV (XBRU:BCART) FCF Margin % : -99.68% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biocartis Group NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biocartis Group NV's Free Cash Flow for the six months ended in Jun. 2023 was €-29.40 Mil. Biocartis Group NV's Revenue for the six months ended in Jun. 2023 was €29.49 Mil. Therefore, Biocartis Group NV's FCF Margin % for the quarter that ended in Jun. 2023 was -99.68%.

As of today, Biocartis Group NV's current FCF Yield % is -188.87%.

The historical rank and industry rank for Biocartis Group NV's FCF Margin % or its related term are showing as below:

XBRU:BCART' s FCF Margin % Range Over the Past 10 Years
Min: -537.97 Med: -195.07 Max: -81.4
Current: -84.87

During the past 11 years, the highest FCF Margin % of Biocartis Group NV was -81.40%. The lowest was -537.97%. And the median was -195.07%.

XBRU:BCART's FCF Margin % is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -12.255 vs XBRU:BCART: -84.87

Biocartis Group NV FCF Margin % Historical Data

The historical data trend for Biocartis Group NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocartis Group NV FCF Margin % Chart

Biocartis Group NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-171.95

-151.61

-98.05

-143.92

-81.40

Biocartis Group NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial															-158.82	-131.60	-93.89	-70.83	-99.68

Competitive Comparison of Biocartis Group NV's FCF Margin %

For the Diagnostics & Research subindustry, Biocartis Group NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocartis Group NV's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's FCF Margin % falls into.

Biocartis Group NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Biocartis Group NV's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-46.792	/	57.481
	=	-81.40 %

Biocartis Group NV's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-29.397	/	29.491
	=	-99.68 %

Biocartis Group NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of Biocartis Group NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocartis Group NV (XBRU:BCART) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocartis Group NV (XBRU:BCART) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Generaal de Wittelaan 11 B, Mechelen, BEL, 2800

Website

https://www.biocartis.com

Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.

Biocartis Group NV (XBRU:BCART) Headlines

No Headlines